About Lorna

This author has not yet filled in any details.
So far Lorna has created 13 blog entries.

Plasticell, Cell and Gene Therapy Catapult and Imperial College London obtain funding to develop manufacturing platform for allogeneic cell immunotherapies

The collaborators have been awarded £800,000 of Innovate UK Biomedical Catalyst funding to develop an integrated and scalable platform to manufacture allogeneic induced pluripotent stem cell (iPSC) derived immunotherapies. The project consortium is led by Plasticell, a biotechnology company developing next-generation stem cell technologies and advanced therapies. The team additionally comprises the Cell and Gene Therapy Catapult (CGT Catapult), an [...]

2023-08-07T22:17:20+01:00August 8th, 2023|Press Releases|

Plasticell and LambdaGen form collaboration to develop iPSC-derived CAR-NK allogeneic cancer immunotherapies

Plasticell Ltd, a developer of stem cell technologies and advanced therapies, has announced today that it has entered into a strategic collaboration with Singapore-based LambdaGen. Together, the two companies will exploit genome editing technologies based on synthetic lambda integrases that allow specific insertion of large gene cassettes into the human genome The UK-Singapore partnership is in part financed by a [...]

2023-05-04T18:31:58+01:00April 25th, 2023|Press Releases|

Plasticell announces completion of £1.4 million equity financing round

Plasticell, the biotechnology company specialising in cell and gene therapy research, has completed an equity financing round raising a total of £1.4 million. Plasticell specialises in using massively parallel screening technologies to discover, develop and optimise manufacturing of high value cell therapies derived from stem cells. Its award-winning combinatorial screening technology, CombiCult®, can be applied to any cell culture process [...]

2021-05-28T18:45:21+01:00May 28th, 2021|Press Releases|

Plasticell obtains further funding to wrap up pre-clinical development of expanded cord blood stem cell product

Plasticell, a developer of stem cell technologies and advanced therapies, has announced it has been awarded Biomedical Catalyst funding to perform a project valued at 594,210 GBP, aimed at concluding pre-clinical development of an ex vivo expanded stem cell product derived from cord blood, in collaboration with Anthony Nolan and the Francis Crick Institute. “This is the fourth time Innovate [...]

2021-05-28T19:04:33+01:00February 25th, 2020|Press Releases|

Plasticell receives EU funding as part of €3.7 million consortium to advance neurodegenerative disease research

Plasticell Ltd, a developer of stem cell technologies and regenerative medicines, has announced that the Advanced Stem Cell Training Network (ASCTN), a European research consortium in which the company is a partner organisation, has successfully bid for over €3,700,000 in funding from the European Union to create and exploit advanced cellular models of neurological disorders – notably Parkinson's, Huntington's and [...]

2021-05-28T20:52:24+01:00October 31st, 2018|Press Releases|

Plasticell wins military contract to develop regenerative medicines for the battlefield

Plasticell, a developer of stem cell technologies and regenerative medicines, has announced that it has been contracted by the Ministry of Defence (MoD) in a pilot programme to develop regenerative medicines for the treatment of injuries resulting from combat or terrorism. Plasticell will deploy its combinatorial stem cell screening platform, CombiCult®, to develop technologies for the conversion of pluripotent stem [...]

2021-05-28T19:06:19+01:00September 4th, 2018|Press Releases|

Plasticell leads gene therapy manufacturing consortium with UCL Great Ormond Street Institute of Child Health (ICH)

UK’s innovation agency provides funding to develop advanced technologies for the manufacturing of autologous ex vivo gene therapies. Plasticell, a developer of stem cell technologies and therapies, has announced it is leading a consortium of pioneering gene therapy groups at UCL Great Ormond Street Institute of Child Health (ICH) to develop advanced technologies for the manufacturing of ex vivo gene [...]

2021-05-28T19:08:09+01:00June 26th, 2018|Press Releases|

Plasticell and Anthony Nolan to partner in clinical trials of ex vivo expanded cord blood stem cells

Plasticell, a developer of innovative stem cell technologies and cell therapies, today announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to saving the lives of people with blood cancers, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product. Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for patients [...]

2021-05-28T19:09:25+01:00December 4th, 2017|Press Releases|

Plasticell and GSK sign collaboration agreement to produce hematopoietic cells from iPSCs

Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult®, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for use by GSK in its therapeutic research. In the collaboration, Plasticell will use its [...]

2021-05-28T19:10:29+01:00October 17th, 2017|Press Releases|

Plasticell and Kings College London to collaborate in trials of blood platelet substitute

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, today announced it has partnered with Kings College London to progress preclinical trials of its artificial blood platelet product, manufactured from pluripotent stem cells. The work is supported by a MedCity research grant which funds collaboration between leading SMEs and academics from London universities. Over 10 million units of [...]

2021-05-28T21:04:13+01:00April 19th, 2017|Press Releases|